YD Bio Limited Ordinary Shares (YDES) Total Return Calculator with Dividends Reinvested

YD Bio Limited Ordinary Shares

Popular:

The total return for YD Bio Limited Ordinary Shares (YDES) stock is -29.82% over the past 12 months. So far it's down 29.58% this year. The 5-year total return is -29.82%, meaning $10,000 invested in YDES stock 5 years ago would be worth $7,018 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in YDES 1 year ago, it would be worth $7,018 today — you'd have lost $2,982.

With Dividends Reinvested$7,018-29.82%

Price Only (No DRIP)$7,018-29.82%

Period2025-08-05 → 2026-03-04

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in YDES

1Y$7,018-$2,982 (-29.8%)-29.8% CAGR

3Y$7,018-$2,982 (-29.8%)-11.1% CAGR

5Y$7,018-$2,982 (-29.8%)-6.8% CAGR

10Y$7,018-$2,982 (-29.8%)-3.5% CAGR

15Y$7,018-$2,982 (-29.8%)-2.3% CAGR

20Y$7,018-$2,982 (-29.8%)-1.8% CAGR

30Y$7,018-$2,982 (-29.8%)-1.2% CAGR

YD Bio Limited Ordinary Shares did not pay dividends during this period. Total return = price return.

Loading YDES total return...

As of 2026-03-05

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-29.58%	—	-29.58%	—	$7,042
1Y	-29.82%	-29.82%	-29.82%	—	$7,018
3Y	-29.82%	-11.13%	-29.82%	—	$7,018
5Y	-29.82%	-6.84%	-29.82%	—	$7,018
10Y	-29.82%	-3.48%	-29.82%	—	$7,018
15Y	-29.82%	-2.33%	-29.82%	—	$7,018
20Y	-29.82%	-1.75%	-29.82%	—	$7,018
30Y	-29.82%	-1.17%	-29.82%	—	$7,018

Risk & Highlights

Best Year+1.25%2025

Worst Year+1.25%2025

Max Drawdown-65.29%2025-09-12 → 2026-02-20

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-28.50%	-28.50%	—	+0.41%	-28.9pp
2025	+1.25%	+1.25%	—	+16.64%	-15.4pp

YDES underperformed the S&P 500 by 46.50pp over the past year (-29.82% vs +16.68%).

Loading summary...

YDES Peers' Total Return

Biotechnology · Top 11 by market cap

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
YDESYD Bio Limited Ordinary Shares	$35M	-21.5%	-29.6%	-29.8%	—	-29.8%	-29.8%	-29.8%
VRTXVertex Pharmaceuticals Incorporated	$121.4B	+4.2%	+5.7%	-2.8%	—	+63.9%	+125.4%	+425.4%
REGNRegeneron Pharmaceuticals, Inc.	$108.4B	+2.7%	+1.6%	+15.1%	+0.5pp	+1.5%	+71.6%	+94.0%
PHGEBiomX Inc.	$82.8B	+38.2%	+194.4%	-48.8%	—	-93.2%	-99.5%	-99.7%
ARGXargenx SE	$46.4B	-8.6%	-10.8%	+17.8%	—	+119.3%	+158.7%	+3159.0%
ALNYAlnylam Pharmaceuticals, Inc.	$43.3B	-1.2%	-18.2%	+31.3%	—	+63.9%	+128.3%	+444.7%
CAICaris Life Sciences, Inc.	$33.2B	-6.5%	-26.4%	-29.1%	—	-29.1%	-29.1%	-29.1%
RPRXRoyalty Pharma plc	$26.8B	+7.6%	+22.7%	+43.1%	+2.7pp	+42.2%	+21.0%	+16.7%
BNTXBioNTech SE	$26.0B	-1.6%	+7.4%	-9.6%	—	-21.1%	+10.1%	+643.8%
MRNAModerna, Inc.	$22.6B	+41.4%	+87.3%	+64.2%	—	-59.9%	-56.3%	+210.8%
ROIVRoivant Sciences Ltd.	$21.4B	+39.6%	+34.6%	+175.9%	—	+275.1%	+197.6%	+183.8%

Compare:YDES vs VRTX YDES vs REGN YDES vs PHGE YDES vs VRTX vs REGN

About YDES Dividend Returns

YD Bio Limited Ordinary Shares (YDES) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of YDES over the past year?

YD Bio Limited Ordinary Shares (YDES) delivered a return of -29.82% over the past year. Since YDES does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in YDES be worth today?

A $10,000 investment in YD Bio Limited Ordinary Shares one year ago would be worth $7,018 today, representing a loss of $2,982.

Q3Does YDES pay dividends?

YD Bio Limited Ordinary Shares (YDES) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For YDES, the total return equals the price-only return.

Q4Did YDES beat the S&P 500?

No, YD Bio Limited Ordinary Shares (YDES) underperformed the S&P 500 by 46.50 percentage points over the past year. YDES delivered a total return of -29.82%, compared to the S&P 500's 16.68%. This means a passive S&P 500 index fund outperformed YDES by 46.50pp during this period.

Q5What is YDES's worst drawdown?

YD Bio Limited Ordinary Shares (YDES) experienced a maximum drawdown of -65.29% over the past year, declining from its peak on 2025-09-12 to its trough on 2026-02-20. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is YDES's long-term total return over 10, 20, or 30 years?

YD Bio Limited Ordinary Shares (YDES) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is -29.8% (-3.5% CAGR) — $10,000 would have grown to $7,018. Over 20 years: -29.8% total return (-1.8% CAGR) — $10,000 → $7,018. Over 30 years: -29.8% total return (-1.2% CAGR) — $10,000 → $7,018. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was YDES's best and worst year?

YD Bio Limited Ordinary Shares's best calendar year was 2025 with a total return of 1.2%. Its worst year was 2025 with a total return of 1.2%. This range shows the volatility investors should expect — the difference between the best and worst year is 0.0 percentage points.